Literature DB >> 16803505

Assessment of pelvic lymph node micrometastatic disease in stages IB and IIA of carcinoma of the uterine cervix.

J H T G Fregnani1, M R D O Latorre, P R Novik, A Lopes, F A Soares.   

Abstract

The objective of this study was to assess the frequency of micrometastatic disease (MID) in pelvic lymph nodes (PLNs) in carcinoma of the uterine cervix (CUC) and to determine the risk of recurrence. The PLNs from 289 patients with CUC (IB and IIA) were studied. Each PLN was assessed via immunohistochemistry using a single histologic section (AE1/AE3). Metastatic deposits were measured and the disease status was classified into three groups: 1) absence of metastatic disease (MOD); 2) MID, one or more metastatic PLN with only isolated tumor cells and/or micrometastases (up to 2 mm); and 3) macrometastatic disease (MAD), presence of one or more metastatic PLN with macrometastases (more than 2 mm). Eleven patients (3.8%) were classified as having MID and 37 (12.8%) as having MAD. The 5-year disease-free survival (DFS) rates for MOD, MAD, and MID were 88.7%, 80.4%, and 50.0%, respectively (P < 0.001). The Cox proportional hazards model showed that MID was an independent variable for recurrence when adjusted for MAD, depth of tumor invasion, severity of inflammatory reaction, and use of adjuvant radiotherapy. We conclude that the frequency of MID in PLN was low. However, patients with MID presented a high risk of recurrence and reduced DFS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16803505     DOI: 10.1111/j.1525-1438.2006.00519.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  8 in total

1.  [S3 guidelines on diagnostics and treatment of cervical cancer: Demands on pathology].

Authors:  L-C Horn; M W Beckmann; M Follmann; M C Koch; P Mallmann; S Marnitz; D Schmidt
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

2.  Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer.

Authors:  Beatrice Cormier; John P Diaz; Karin Shih; Rachael M Sampson; Yukio Sonoda; Kay J Park; Khaled Alektiar; Dennis S Chi; Richard R Barakat; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2011-05-13       Impact factor: 5.482

3.  Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer.

Authors:  Behrouz Zand; Elizabeth D Euscher; Pamela T Soliman; Kathleen M Schmeler; Robert L Coleman; Michael Frumovitz; Anuja Jhingran; Lois M Ramondetta; Pedro T Ramirez
Journal:  Gynecol Oncol       Date:  2010-09-15       Impact factor: 5.482

4.  Sentinel lymph node biopsy in the management of early-stage cervical carcinoma.

Authors:  John P Diaz; Mary L Gemignani; Neeta Pandit-Taskar; Kay J Park; Melissa P Murray; Dennis S Chi; Yukio Sonoda; Richard R Barakat; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2011-01-08       Impact factor: 5.482

5.  Sentinel lymph node detection rates using indocyanine green in women with early-stage cervical cancer.

Authors:  Anna L Beavis; Sergio Salazar-Marioni; Abdulrahman K Sinno; Rebecca L Stone; Amanda N Fader; Antonio Santillan-Gomez; Edward J Tanner
Journal:  Gynecol Oncol       Date:  2016-08-12       Impact factor: 5.482

6.  Comment on 'Contribution of pelvic and para-aortic lymphadenectomy with sentinel node biopsy in patients with IB2-IIB cervical cancer'.

Authors:  A Peres; A-L Margulies; E Barranger
Journal:  Br J Cancer       Date:  2012-06-07       Impact factor: 7.640

7.  Abdominal radical trachelectomy guided by sentinel lymph node biopsy for stage IB1 cervical cancer with tumors >2 cm.

Authors:  Xiangyun Deng; Ying Zhang; Dapeng Li; Xiaoling Zhang; Hui Guo; Fei Wang; Xiugui Sheng
Journal:  Oncotarget       Date:  2017-01-10

8.  Human papillomavirus types 16 and 18 and the prognosis of patients with stage I cervical cancer.

Authors:  Rossana de Araújo Catão Zampronha; Ruffo Freitas-Junior; Eddie Fernando Candido Murta; Márcia Antoniazi Michelin; Aline Almeida Barbaresco; Sheila Jorge Adad; Amaurillo Monteiro de Oliveira; Amanda B Rassi; Glória Jabur Bittar Oton
Journal:  Clinics (Sao Paulo)       Date:  2013-06       Impact factor: 2.365

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.